VERONA PHARMA PLC - AMERICAN DEPOSITARY SHARES

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

27 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Verona Pharma Announces March 2025 Investor Conference Participation

18 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

13 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

07 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Verona Pharma Announces December 2024 Investor Conference Participation

19 Nov 2024 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present at Jefferies London Healthcare Conference

05 Nov 2024 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

04 Nov 2024 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

21 Oct 2024 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024

30 Sep 2024 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

05 Sep 2024 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

08 Aug 2024 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

30 Jul 2024 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

25 Jul 2024 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

26 Jun 2024 15:57:26 By Nasdaq GlobeNewswire

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

09 May 2024 06:15:00 By Nasdaq GlobeNewswire

Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS

09 May 2024 06:00:01 By Nasdaq GlobeNewswire

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

02 May 2024 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update

25 Apr 2024 01:00:00 By Nasdaq GlobeNewswire

Andrew Fisher Joins Verona Pharma as General Counsel

04 Mar 2024 01:00:00 By Nasdaq GlobeNewswire

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

29 Feb 2024 01:00:00 By Nasdaq GlobeNewswire